Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7351993 | 0.89 | — | — | |
| SCHEMBL7904797 | 0.87 | ALDH1A1 (0.44) | SMOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12015831 | 0.82 | PAOX (0.39) | SMODRD2 | |
| SCHEMBL7910011 | 0.80 | DRD2 (0.45) | SMOMEN1KMT2ADRD2 | |
| SCHEMBL16190266 | 0.80 | POLB (0.35) | SMOALDH1A1KMT2AKDM4EDRD2 | |
| SCHEMBL6423485 | 0.80 | PTGS1 (0.33) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12015832 | 0.79 | CARM1 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL24911710 | 0.78 | ALOX15 (0.39) | SMODRD2 | |
| SCHEMBL22878436 | 0.78 | SMO (0.34) | SMODRD2 | |
| SCHEMBL17284206 | 0.78 | GNAI3 (0.44) | SMODRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133262-B2 | Somatostatin antagonists | IPSEN PHARMA S.A.S. (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133262-B2 | Somatostatin antagonists | IPSEN PHARMA S.A.S. (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20090253638-A1 | Somatostatin Antagonists | BIOMEASURE, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| US-20090253638-A1 | Somatostatin Antagonists | BIOMEASURE, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| US-7550423-B2 | Somatostatin antagonists | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550423-B2 | Somatostatin antagonists | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253638-A1 | Somatostatin Antagonists | SSTR5, SSTR2, SSTR4 | SMO 625/4885ALDH1A1 4519/4885MEN1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.